Register to receive a free Interventional Cardiology Devices Market Report Suite for Europe 2018-2024 synopsis and brochure
Teleflex Incorporated announced that it has acquired Essential Medical, Inc. Based in Exton, PA, Essential Medical is a privately-held medical device company that has developed and commercialized the CE Marked MANTA™ Vascular Closure Device specifically designed for closure of large bore arteriotomies following procedures utilizing devices or sheaths ranging in size from 10F to 18F (with maximum outer diameters up to 25F). In its CE Mark study, the MANTA Device demonstrated rapid and reliable hemostasis with its resorbable collagen-based technology and complication rates that were non-inferior to surgical and suture-based closure methods.
“We are very excited to announce this acquisition, which expands our presence in the structural heart and endovascular aneurysm repair markets,” said Liam Kelly, President and Chief Executive Officer of Teleflex. Added Mr. Kelly, “The MANTA Vascular Closure Device represents a truly innovative solution to address closure-related complications and high costs associated with many large and rapidly growing interventional procedure categories, such as transcatheter aortic valve replacement, endovascular aneurysm repair and ventricular assist device implantation. Physician adoption of the MANTA Device in international markets has been impressive, with over 8,100 procedures completed to date across a number of countries in the EU. We believe we can leverage our strong presence in the interventional cardiology market to accelerate adoption and growth of this breakthrough technology worldwide. Following the anticipated FDA premarket approval of the MANTA Device in 2019, we expect the acquisition will be modestly accretive to our constant currency revenue growth and gross margins over a multi-year period.”
“The combination of Teleflex and Essential Medical provides an excellent opportunity to maximize physician and patient access to the MANTA™ Vascular Closure Device,” stated Greg Walters, Essential Medical’s co-founder, President and CEO. “We are delighted to become an important part of Teleflex’s interventional cardiology business.”
The MANTA Device is not approved for sale or distribution in the United States.
For Further Market Information
More can be found in a series of reports published by iData Research entitled the Europe Market Report Suite for Interventional Cardiology Devices 2018. This research includes coronary stents, coronary balloon catheters, interventional coronary catheters and guidewires, introducer sheaths, coronary embolic protection devices, coronary atherectomy devices, coronary vascular closure devices, diagnostic coronary catheters and guidewires, coronary intravascular ultrasound (IVUS) catheters and coronary optical coherence tomography (OCT) catheters.
iData’s suite of reports on this subject covers the United States, Japan, and 15 countries in Europe. These include a comprehensive analysis on units sold, market values, average selling prices, forecasts, procedure data, as well as detailed competitive market shares and analysis of all major players. In addition, the research includes product assessments, product pipelines, recalls as well as SWOT analyses.
Email us at email@example.com or register online for an Europe Market Report Suite for Interventional Cardiology Devices 2018 brochure and free sample.